Exscientia Plc (EXAI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exscientia Plc has announced its acquisition of full rights to a promising CDK7 inhibitor, GTAEXS617, from GT Apeiron, with phase 1/2 clinical trial data expected in the latter half of 2024 and a combination study to follow soon after. The drug, designed using AI, shows potential in treating various advanced solid tumors and could significantly improve treatment options for cancer patients. Exscientia’s financial commitment includes an upfront payment and royalties, maintaining a solid cash runway projected to last into 2027.
For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.